Hazardous drugs and USP <800>

USP <800> and the NIOSH hazardous-drug definition, the three HD types, routes of exposure, safety data sheets and what a technician is actually required to do.

USP General Chapter <800> — Hazardous Drugs

USP General Chapter <800> sets the operational standard for how healthcare sites receive, store, prepare, transport, administer, and clean up hazardous drugs. Whether <800> carries the force of law depends on state adoption, accreditation requirements, and employer policy — but in practice, most sites treat it as baseline.

The protection rules in USP <800> extend well beyond pharmacists and pharmacy technicians. Nurses, physicians, physician assistants, home-care staff, and veterinary personnel are all expected to work under USP <800> when they may touch a hazardous drug or contaminated waste. Anyone handling hazardous drugs must complete role-appropriate training and demonstrate continued competency on a scheduled basis.

Exam Tip: The PTCE tests USP <800> by number. Memorize the chapter number (<800>), and keep it distinct from <795> (nonsterile compounding) and <797> (sterile compounding).

NIOSH Hazardous-Drug Definition

NIOSH classifies a medication as hazardous when evidence in humans or animals shows at least one of six recognized hazard characteristics:

1. Carcinogenicity — can cause cancer.
2. Teratogenicity or other developmental toxicity — can cause birth defects.
3. Reproductive toxicity — can impair fertility or damage reproductive function.
4. Organ toxicity at low doses — damage at low exposure levels.
5. Genotoxicity — DNA or chromosomal damage.
6. Structural or toxicologic similarity to existing hazardous drugs — new agents resembling classified hazardous agents may be handled as hazardous pending review.

NIOSH Tables 1 and 2

The December 2024 NIOSH hazardous-drug list separates agents into two groups based on the strength of carcinogenicity evidence and the availability of manufacturer safe-handling guidance.

The 2024 update also adds selected drugs to the hazardous list based on developmental or reproductive toxicity alone — confirming that hazardous handling is not limited to carcinogens.

Three HD Types under USP <800>

USP <800> groups hazardous drugs into three categories:

1. Antineoplastic — cancer-fighting agents such as chemotherapy drugs.
2. Nonantineoplastic — hazardous but not used for cancer treatment.
3. Reproductive risk only — primary risk is to reproductive health.

Health Effects of HD Exposure

• Immediate: dermatitis, dizziness, nausea, headache.
• Long-term, low-dose repeated exposure: organ damage, chromosomal damage, impaired fertility, cancer.

Common Trap: The PTCE sometimes pairs a non-chemotherapy hazardous drug with a distractor set that looks antineoplastic-only. Warfarin, estradiol, ethinyl estradiol/levonorgestrel, oxcarbazepine, and colchicine are all hazardous under NIOSH, and none are chemotherapy agents. Do not limit "hazardous drug" to oncology.

Safety Data Sheets (SDS) — OSHA Hazard Communication

Each hazardous chemical used in the pharmacy must have an available Safety Data Sheet. Manufacturers, distributors, and importers are legally responsible for supplying the SDS, and OSHA requires that SDSs remain readily accessible to workers handling hazardous chemicals.

An SDS summarizes:

• Basic chemical properties.
• Physical, health, and environmental risks.
• Recommended protective measures.
• Safe practices for handling, storage, and transport.

Reference the SDS:

• Before handling, storing, or transporting a hazardous substance.
• Whenever a spill or exposure occurs.
• Any time questions arise about the chemical's hazards.

Definition: A Safety Data Sheet is the required document for each hazardous chemical that summarizes hazards, protective measures, and handling, storage, and transport precautions.

Routes of Hazardous-Drug Exposure

Exposure can happen at every stage of the drug's trip through the pharmacy:

• Receiving: residue may already be on cartons, vials, unit-dose packaging, shelving, or floors.
• Dispensing: counting, repackaging, and handling contaminated packaging can spread residue.
• Compounding or manipulation: crushing, splitting, reconstituting, drawing up injectables, and cleaning contaminated equipment can all release particles.
• Administration: aerosols, tubing priming, and certain specialized procedures expose staff.
• Patient care: body fluids, contaminated clothing, linens, and dressings may carry hazardous residue.
• Spill response, transport, and waste handling: each step risks new contamination if procedures fail.

Risk Assessment Factors (USP <800>)

A USP <800> risk assessment accounts for all of the following:

• The type of hazardous drug (antineoplastic, nonantineoplastic, reproductive-risk only).
• Its dosage form.
• The likelihood that staff will be exposed during handling.
• Whether the package stays intact or must be manipulated before use.

Engineering Controls

Primary Engineering Controls (C-PECs) for Sterile Hazardous Compounding

A C-PEC (Containment Primary Engineering Control) is the containment workstation where hazardous sterile compounding happens. It protects the preparer and the product simultaneously.

• A biological safety cabinet (BSC) is one C-PEC type. For hazardous sterile work, the C-PEC is a Class II BSC — most commonly Type A2 (Type B2 is used for volatile hazardous drugs) — externally vented.
• A CACI (compounding aseptic containment isolator) is the other common C-PEC. It is a closed isolator accessed through attached flexible glove sleeves or gauntlets. Supplies enter through a pass-through chamber sealable from both the main chamber and outside environment.
• All materials placed in the pass-through must be wiped down with disinfectant first. The pass-through must be sealed and pressurized to match the compounding chamber before materials can be retrieved.
• Every C-PEC used for hazardous sterile compounding must be externally vented to remove airborne hazardous particles.
• C-PECs must operate continuously, even when compounding is not in progress.
• C-PECs must be inspected and certified by qualified personnel every 6 months.

Exam Tip: The C-PEC for hazardous sterile work is a Class II BSC (commonly Type A2; Type B2 for volatile drugs) or a CACI, externally vented. The trap answer is a horizontal laminar-airflow workbench (no personnel containment at all) or a Class II Type A1 cabinet — a containment device, but with only 75 ft/min minimum inflow against a Type A2's 100 ft/min, so not acceptable for hazardous drugs.

Closed-System Transfer Devices (CSTDs)

A CSTD is a vial transfer system designed so hazardous drugs cannot be vented or exposed to the surrounding environment during compounding. Internal vial pressure during hazardous-drug reconstitution can create spills, aerosols, and surface contamination; the CSTD blocks that pathway. USP <800> and common practice call for CSTD use during hazardous-drug compounding whenever the dosage form allows it.

Definition (plain-language): A CSTD seals the path between the vial and the syringe so no hazardous aerosol, vapor, or liquid escapes during transfer.

Air Quality Requirements (USP <800>)

Exam numbers to memorize: The required pressure differential for a C-SEC is −0.01 to −0.03 inches of water column relative to adjacent areas. Buffer rooms maintain at least 30 ACPH and ISO Class 7. C-SCAs maintain at least 12 ACPH and must be externally vented.

Mnemonic: "30 / 30 / 12 ACPH" — Buffer (negative) = 30, Anteroom = 30, C-SCA = 12. Pair with "0.01 to 0.03 — Negative C-SEC" and "Ozone Outside (Externally Vented, Every 6 Months)." See the Mnemonic Library cheat sheet Section 6.

A C-SCA is not interchangeable with a full cleanroom suite. Under USP <797>, a Containment Segregated Compounding Area supports only Category 1 compounded sterile preparations (the shortest-BUD category). Category 2 and Category 3 CSPs require a full ISO Class 7 cleanroom suite — a C-SEC buffer room with its accompanying anteroom. A site that needs the longer beyond-use dating of Category 2 or 3 cannot rely on a C-SCA.

Negative-Pressure Storage

• Antineoplastic hazardous drugs received outside protective final packaging must move quickly into the designated negative-pressure HD storage area, not sit with routine inventory.
• Hazardous waste belongs only in approved hazardous-waste containers located in the appropriate negative-pressure area.

Personal Protective Equipment (PPE)

Technique matters most, but PPE is a core protective layer for anyone handling or preparing hazardous drugs. USP <800> requires PPE for compounding, administering, cleaning, and disposing of hazardous-drug waste.

Full PPE List

• Gloves: two pairs of chemotherapy-tested gloves meeting ASTM D6978.
• Gown: impermeable, back-closing, long-sleeved, with tight-fitting cuffs.
• Shoe covers: as required by the task or area.
• Head and hair covers: required in hazardous compounding areas.
• Eye/face protection: used when splash risk exists.
• Respirator: required when aerosol generation or spill cleanup creates inhalation risk.

Gown Requirements (Detail)

• Validated as impermeable to liquid spills and splashes.
• Solid front.
• Made of lint-free material.
• Long sleeves with tight-fitting elastic or knit cuffs.
• Kept inside the hazardous-drug area — do not wear into clean or public spaces.
• Changed immediately if contaminated.

Glove Protocol

• Hazardous-drug work requires chemotherapy-rated gloves meeting ASTM D6978.
• Wash hands before gloving and again after glove removal.
• For all cytotoxic and hazardous substance procedures, two pairs of gloves are required, and the outer pair must be sterile when sterile compounding is underway. Double gloving applies whenever antineoplastics or other cytotoxic agents are prepared in a sterile environment.
• Replace any glove that is torn, punctured, or visibly contaminated immediately.
• Touch the outside of hazardous-waste containers only with gloves that have not been contaminated by the task.

Double-Gloving Technique

• First (inner) pair goes under the gown cuff.
• Second (outer) pair goes over the gown cuff.

This creates a continuous sealed barrier between skin and hazardous-drug residue.

Eyewash and First Aid

• Hazardous-drug work areas require nearby eyewash and first-aid access.
• For skin or eye contact, begin the facility's first-aid steps immediately, obtain prompt medical evaluation, and document the exposure per policy.
• OSHA 15-minute rule: when a hazardous chemical or drug contacts the eye, irrigate the eye at an eyewash fountain or with water or isotonic eyewash solution for at least 15 minutes. The 15-minute duration is the testable number.

OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030)

The OSHA Bloodborne Pathogens Standard protects pharmacy and healthcare employees from occupational exposure to blood and other potentially infectious materials.

• Training is required at initial assignment and at least annually thereafter.
• Training must be offered at no cost to the employee during working hours.
• Program elements include exposure-control plans, engineering and work-practice controls, PPE, Hepatitis B vaccination offered within 10 working days of assignment, sharps-injury logs, and post-exposure evaluation and follow-up.

Common Trap: OSHA bloodborne pathogens training is annual (every year). DEA controlled-substance inventory is biennial (every 2 years). Watch for a distractor that swaps these two.

Receiving and Storing Hazardous Drugs

Receipt and storage of hazardous drugs happen before compounding, and exposure can begin at the door. Shipments are typically separated from routine inventory, and receiving staff open them wearing appropriate PPE with attention to leakage or damage. After receipt, containers are wiped down, kept apart from ordinary stock, and placed in the designated storage area specified by policy and the site's risk assessment.

Labeling

Hazardous drugs must carry clear, distinctive labeling so staff recognize special handling precautions before touching the product.

Storage Area

• Obvious hazard signage at the storage entrance.
• Storage fixtures designed to reduce the chance a hazardous container will fall or shatter — such as shelves with front barriers and carts with rims.
• Access restricted to trained, authorized staff.

Transport

• Hazardous-drug transport must reduce the chance of leaks, drops, or broken containers.
• Pneumatic tubes must not be used to transport any liquid HDs or any antineoplastic HDs — a categorical USP <800> Section 11 requirement (breakage and contamination risk), not a site-by-site policy choice.
• Transport carts and outer packaging must physically protect the containers and keep them upright and sealed.

Spill Management

Hazardous-drug spills are handled with a designated spill kit and the site's written cleanup procedure. Staff who may respond to a spill need to know where the kit is kept and what PPE or respirator requirements apply before an incident, not after.

Spill Kit Contents

• Chemotherapy-tested gloves and protective apparel.
• Face and eye protection.
• Absorbent cleanup materials.
• Labeled hazardous-waste bags or other approved containers.
• Tools for broken-glass pickup.
• A puncture-resistant container.
• The decontamination or cleanup supplies required by facility policy.

Spill Cleanup Procedure (8 Steps)

1. Secure the area — post a warning sign so others do not enter the spill zone.
2. Don all necessary PPE, including two pairs of gloves.
3. Pick up broken glass and place it in the puncture- and leak-resistant container.
4. Absorb liquids with disposable towels or spill pads.
5. Remove powders with dampened towels or gauze.
6. Decontaminate and clean the surface with agents appropriate for the specific hazardous drug.
7. Store hazardous waste in leak-resistant containers until disposed of per government and institutional policy.
8. Document the circumstances and handling of the spill in an incident report and keep it on file.

Pharmacist Call Required: Any hazardous-drug spill is a pharmacist-notification event, even if the technician is performing the cleanup. Do not wait until the spill is contained to notify the PIC — the pharmacist's visibility on the incident starts at discovery, not at the end.

Cleaning Requirements under USP <800>

The Four-Step Cleaning Sequence

USP <800> uses a deliberate four-part sequence to reduce contamination in hazardous-drug areas:

1. Deactivation — neutralize the hazardous compound when possible.
2. Decontamination — remove residue from the work surface.
3. Cleaning — remove soil and remaining material.
4. Disinfection — complete the germicidal step required for sterile environments.

Mnemonic: "DDCD" — Deactivation → Decontamination → Cleaning → Disinfection. Tested order; cannot skip steps. See the Mnemonic Library cheat sheet Section 6.

Cleaning Agents

• Facilities commonly use diluted peroxide or sodium hypochlorite with low-lint wipes for deactivation and decontamination.
• Because the environment still supports sterile compounding, the area requires the usual cleaning and disinfection steps afterward, often ending with sterile IPA per site policy.

Cleaning Frequency

• At the start of each shift and periodically during ongoing compounding.
• After a spill or possible contamination event has been deactivated and decontaminated.
• If power to the C-PEC is lost, use must stop immediately. After power is restored, all PEC surfaces must be decontaminated, cleaned, and disinfected, and compounding cannot resume until the manufacturer's specified recovery time has elapsed.

Records and Logs

• Every site should establish written cleaning expectations for the C-PEC, C-SEC, and any surrounding areas that may contact hazardous residue.
• Cleaning records must be maintained per policy.
• Used wipes, pads, and cleanup materials go into the correct hazardous-waste stream.
• Staff performing deactivation, decontamination, or disinfection must wear the PPE required for the task.

Waste Disposal

Every site needs a written process for identifying, segregating, collecting, and discarding hazardous-drug waste. Only approved hazardous-waste containers are used for that stream, and regular trash stays out of those containers.

Hazardous Drug vs. Hazardous Waste

Common Trap: "Hazardous drug" (NIOSH/USP <800>) and "hazardous waste" (EPA/RCRA) are different regulatory categories. A drug may require hazardous-drug handling precautions without being EPA hazardous waste, and vice versa at disposal. Check both classifications — the PTCE tests this distinction directly.

RCRA Enforcement

Hazardous-waste rules are enforced by the US Environmental Protection Agency (EPA), often together with the relevant state hazardous-waste authority.

Common EPA-Listed Hazardous-Waste Pharmaceuticals

PTCE focus: Warfarin waste is concentration-dependent. Commercial chemical products with more than 0.3% warfarin are P001 acute hazardous waste. Warfarin at 0.3% or less is U248 hazardous waste. This split is a classic PTCE distractor — know both codes.

P042 nuance (post-EPA 2019 Final Rule): P042 applies only to epinephrine free base (CAS 51-43-4). Epinephrine salt forms (hydrochloride, bitartrate, borate) and residues remaining in used syringes after injection are not regulated as P042. Most hospital and pharmacy epinephrine waste is no longer P042 under current EPA interpretation. For PTCE purposes, recognize that "P042 = epinephrine" is still the common test shorthand, with the salt-form caveat becoming increasingly relevant in practice.

Environmental Concerns

Improper medication disposal creates public-health and environmental concerns. Some drug residues remain active even after wastewater treatment, which is why routine sewer or landfill disposal is heavily scrutinized. Examples of environmentally concerning residues include hormones, antimicrobials, and other active pharmaceutical byproducts found in water systems.

EPA and state enforcement of pharmaceutical-disposal rules has grown more serious as environmental concern has increased. Compliance is resource-intensive and non-negotiable.

Safe pharmaceutical disposal is not solely a pharmacist issue. Everyone who handles medication waste shares responsibility for staff safety, patient safety, and environmental protection.

Non-Returnable Pharmaceutical Disposal

For ordinary nonhazardous return, credit, investigational, and reverse-distribution workflow, see Study Guide 4.4: Returns and Disposal. This chapter focuses on hazardous-drug and hazardous-waste handling only.

FDA-Cleared Sharps Containers

An FDA-cleared sharps container is rigid and puncture-resistant, holds fluid without leaking through its sides or base, and closes with a snug, puncture-resistant lid. Used needles and syringes drop straight in — never recapped, never dropped in the regular trash.

CDC Hand Hygiene

Hand hygiene is the CDC's first-line defense against the spread of infection in healthcare settings; no other single measure accomplishes as much. Clean your hands before and after patient contact, before and after using gloves, after handling contaminated items, and any time they are visibly soiled.

Policies, Training, and Quality

The quality-assurance requirements below apply specifically to hazardous-drug compounding under USP <800> and overlap with sterile compounding standards under USP <797>.

Common Traps

Here's where people miss it on Section 2.1. The chapter scatters these warnings inline as you read; this section pulls them together so they are easy to drill before the exam.

• Limiting "hazardous drug" to oncology. Hazardous drugs are not only chemotherapy agents. Warfarin, estradiol, ethinyl estradiol/levonorgestrel, oxcarbazepine, and colchicine are all hazardous under NIOSH and none are antineoplastics. USP <800> recognizes three categories — antineoplastic, nonantineoplastic, and reproductive-risk only.
• Swapping the OSHA-annual and DEA-biennial intervals. OSHA bloodborne-pathogens training is annual (every year). DEA controlled-substance inventory is biennial (every 2 years). The exam writes this swap as a classic distractor.
• Treating "hazardous drug" and "hazardous waste" as one category. "Hazardous drug" is a NIOSH / USP <800> classification; "hazardous waste" is an EPA / RCRA classification. A drug can be one, the other, or both. Check both frameworks — the disposal answer depends on the EPA code, not the handling category.
• Missing the warfarin P-list / U-list split. Warfarin waste is concentration-dependent. Commercial chemical products with more than 0.3% warfarin are P001 acute hazardous waste; warfarin at 0.3% or less is U248 hazardous waste. Know both codes.
• Answering with the wrong C-PEC. Hazardous sterile compounding requires a Class II BSC (most commonly Type A2; Type B2 for volatile drugs) or a CACI, externally vented. A horizontal laminar-airflow workbench provides no personnel containment at all, and a Class II Type A1 cabinet, though a real containment device, is not acceptable for hazardous drugs — its minimum inflow velocity is only 75 ft/min, against the 100 ft/min a Type A2 provides. Both are wrong answers.
• Confusing the USP chapter numbers. <800> is hazardous drugs, <797> is sterile compounding, <795> is nonsterile compounding. The exam tests <800> by number.
• Confusing NIOSH with OSHA. NIOSH researches and classifies hazards (it is part of the CDC and is not a regulatory agency). OSHA is the regulatory and enforcement arm for workplace safety.
• Missing the certification interval. C-PECs are inspected and certified every 6 months — not annually — and must operate continuously even when compounding is not in progress.
• Forgetting the eyewash duration. After a hazardous chemical or drug contacts the eye, the OSHA rule is irrigation for at least 15 minutes. The 15-minute number is the testable fact.
• Overlooking patient-care exposure. The most overlooked route of hazardous-drug exposure is patient care — body fluids, contaminated linens, dressings, and clothing can all carry hazardous residue.
• Skipping the pharmacist on a spill. Any hazardous-drug spill is a pharmacist-notification event, even when the technician performs the cleanup. The PIC's visibility starts at discovery, not at the end of containment.
• Mishandling the post-needlestick sequence. After a needlestick the worker washes with soap and water first, then reports to the supervisor; paperwork and infection-control notification follow the first-aid action.

Quick Review Checklist

A fast scan of the highest-yield Section 2.1 facts. If any line does not land, go back to the matching body section before moving on.

• USP chapters — <800> hazardous drugs, <797> sterile compounding, <795> nonsterile compounding.
• Six NIOSH hazard characteristics — carcinogenicity, teratogenicity/developmental toxicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, structural/toxicologic similarity to existing hazardous drugs.
• Three USP <800> HD categories — antineoplastic, nonantineoplastic, reproductive-risk only.
• C-PEC for hazardous sterile work — Class II BSC (most commonly Type A2; Type B2 for volatile drugs) or a CACI with pass-through chamber; externally vented; continuous operation; certified every 6 months.
• Air quality — C-PEC interior ISO Class 5; buffer room (C-SEC) ISO Class 7, 30 ACPH, negative; C-SCA 12 ACPH, externally vented, not ISO-classified; anteroom ISO Class 7, 30 ACPH, positive.
• C-SEC pressure differential — −0.01 to −0.03 inches of water column relative to adjacent areas.
• CSTD — closed-system transfer device; prevents hazardous vapor, aerosol, or liquid escape during transfer.
• Gloves — chemotherapy-tested, ASTM D6978; double-glove (inner pair under the gown cuff, outer pair over); the outer pair is sterile for cytotoxic sterile compounding.
• OSHA eyewash — irrigate the eye for at least 15 minutes after chemical/drug eye contact.
• OSHA bloodborne pathogens (29 CFR 1910.1030) — training at initial assignment and annually; Hepatitis B vaccine offered within 10 working days of assignment.
• DEA controlled-substance inventory — biennial (every 2 years) — do not swap with the annual OSHA training interval.
• Four-step cleaning sequence — deactivation, decontamination, cleaning, disinfection (cannot skip steps).
• Spill cleanup order — secure the area, don PPE, pick up broken glass, absorb liquids, remove powders, decontaminate/clean, contain waste, document.
• Hazardous drug vs. hazardous waste — NIOSH/USP <800> vs. EPA/RCRA; check both frameworks.
• EPA P-list/U-list — P001 warfarin >0.3%, U248 warfarin ≤0.3%, P042 epinephrine, P075 nicotine, P081 nitroglycerin, P188 physostigmine. RCRA is enforced by the EPA.

Related

DEA schedules, refills and transfers · What is on the PTCE and how it is weighted · All Federal Requirements guides